NKGen Biotech Amends $5 Million BDW Loan, Pledging Real Estate as First-Lien CollateralTradingView·Jul 17 at 04:03 PMNKGN0.00%
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions | NKGN Stock NewsStockTitan·Jul 1 at 11:05 PMNKGN0.00%
NKGen Biotech Expands AlpineBrook Convertible Loan; Adds $412,500 Note at $0.08 and More SharesTradingView·May 21 at 04:23 PMNKGN0.00%
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment | NKGN Stock NewsStockTitan·May 18 at 11:05 PMNKGN0.00%IBBQ-2.77%
07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026prnewswire·May 5 at 06:38 AMNKGN0.00%PRTG0.00%
NKGen Biotech Secures Additional Convertible Financing and WarrantsTip Ranks·May 4 at 06:16 PMNKGN0.00%XLV-1.87%
NKGen Biotech Announces Major Convertible Financing and Governance ShiftTip Ranks·Apr 21 at 05:10 PMNKGN0.00%LABU-10.73%
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference | KNBIF Stock NewsStockTitan·Apr 15 at 10:25 PMNKGN0.00%LABU-10.73%
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit | NKGN Stock NewsStockTitan·Apr 8 at 11:05 PMARKG-0.19%SBIO-3.15%
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | NKGN Stock NewsStockTitan·Mar 22 at 11:05 PMFBT-1.38%XLV-1.87%
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms | KNBIF Stock NewsStockTitan·Mar 16 at 10:25 PMNKGN0.00%IBB-2.83%
